<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069350</url>
  </required_header>
  <id_info>
    <org_study_id>Topical anesthesia in IVI</org_study_id>
    <nct_id>NCT05069350</nct_id>
  </id_info>
  <brief_title>Bupivacaine vs Oxybuprocaine Topical Anesthesia in IVI</brief_title>
  <official_title>A Double Blinded Randomized Controlled Study of Topical Anaesthetics Oxybuprocaine Versus Bupivacaine 0.5% in Intravitreal Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute of Ophthalmology, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Institute of Ophthalmology, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      comparing two local anaesthetic agents, Bupivacaine 0.5% versus Oxybuprocaine used topically&#xD;
      to provide surface anaesthesia before IVI procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preparation zone, we will cannulate the patients, connect them to the pulse oximetry and&#xD;
      we will start providing appropriate surface anaesthesia for an adequate period of time before&#xD;
      the patient administration of the injection, by applying the anaesthetic agents, 3 times with&#xD;
      5 minutes interval, for 15 minutes and then waitng the injection&#xD;
&#xD;
      All patients are informed that they are going to receive topical anaesthetic agent before the&#xD;
      IVI.&#xD;
&#xD;
      pain is monitored during the injection by using the 11 points verbal numerical pain scaling&#xD;
      as zero is for no pain and 10 is for severe unbearable pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blinded randomized syudy</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>verbal pain numerical scaling</measure>
    <time_frame>10 minutes</time_frame>
    <description>11 point scale from 0-10 zero measns No pain 10 means severe unbearable pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>bupivacaine 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>oxybuprocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine 0.5% and oxubuprocaine</intervention_name>
    <description>using each drug as surface anesthesia before intravitreal injections</description>
    <arm_group_label>bupivacaine 0.5%</arm_group_label>
    <arm_group_label>oxybuprocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients between 30 to 70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncooperative patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abeer Samir</last_name>
    <phone>01125666006</phone>
    <email>abeersamirali@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>dina moustafa</last_name>
    <phone>01033705791</phone>
    <email>dina.moustafa.ali@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Institute of Ophthamology</name>
      <address>
        <city>Giza</city>
        <state>Haram</state>
        <zip>12513</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abeer Samir, M.D</last_name>
      <phone>01125666006</phone>
      <email>abeersamirali@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>dina moustafa, M.D</last_name>
      <phone>0103370591</phone>
      <email>dina.moustafa.ali@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

